Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 14/20 | 0.53 |
| ▸ | ALDH1A1 | P00352 | 11/20 | 0.53 |
| ▸ | HSD17B10 | Q99714 | 5/20 | 0.53 |
| ▸ | HPGD | P15428 | 5/20 | 0.53 |
| ▸ | MAPT | P10636 | 4/20 | 0.53 |
| ▸ | ATM | Q13315 | 3/20 | 0.53 |
| ▸ | GLA | P06280 | 3/20 | 0.53 |
| ▸ | GAA | P10253 | 3/20 | 0.53 |
| ▸ | CASP1 | P29466 | 1/20 | 0.53 |
| ▸ | CASP7 | P55210 | 1/20 | 0.53 |
| ▸ | CA1 | P00915 | 3/20 | 0.49 |
| ▸ | CA2 | P00918 | 3/20 | 0.49 |
| ▸ | CA12 | O43570 | 2/20 | 0.49 |
| ▸ | CA7 | P43166 | 2/20 | 0.49 |
| ▸ | CA9 | Q16790 | 2/20 | 0.49 |
| ▸ | CA14 | Q9ULX7 | 2/20 | 0.49 |
| ▸ | XDH | P47989 | 1/20 | 0.49 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.46 |
| ▸ | ALOX15 | P16050 | 2/20 | 0.46 |
| ▸ | HTT | P42858 | 2/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL607301 | 0.86 | KDM4E (0.57) | KDM4EALDH1A1HSD17B10HPGDMAPT | |
| SCHEMBL7014396 | 0.84 | ALDH1A1 (0.55) | KDM4EALDH1A1HSD17B10HPGDMAPT | |
| SCHEMBL879847 | 0.83 | ALDH1A1 (0.49) | KDM4EALDH1A1HSD17B10HPGDMAPT | |
| SCHEMBL29732495 | 0.83 | CA1 (0.62) | KDM4EALDH1A1HSD17B10HPGDMAPT | |
| SCHEMBL15563640 | 0.83 | CA1 (0.62) | KDM4EALDH1A1HSD17B10HPGDMAPT | |
| SCHEMBL23292610 | 0.81 | KDM4E (0.55) | KDM4EALDH1A1HSD17B10HPGDMAPT | |
| SCHEMBL15338330 | 0.81 | GAA (0.56) | KDM4EALDH1A1HSD17B10HPGDMAPT | |
| SCHEMBL27892855 | 0.81 | PLA2G2A (0.45) | KDM4EALDH1A1HPGDMAPTGAA | |
| SCHEMBL16008419 | 0.81 | ABL1 (0.54) | KDM4EALDH1A1HPGDMAPTGLA | |
| SCHEMBL4129101 | 0.81 | CA1 (0.47) | KDM4EALDH1A1HSD17B10HPGDMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-103002735-B | Modulators of 5-ht receptors and methods of use thereof | ABBVI CO | 2015-05-20 | — | — | CN | disclosed |
| US-7220780-B2 | Naaladase inhibitors for treating retinal disorders and glaucoma | GUILFORD PHARMACEUTICALS INC. (US) | 2007-05-22 | — | — | US | disclosed |
| US-7220780-B2 | Naaladase inhibitors for treating retinal disorders and glaucoma | GUILFORD PHARMACEUTICALS INC. (US) | 2007-05-22 | — | — | US | disclosed |
| US-20050171065-A1 | NAALADas, N-Acetylated-Alpha-Linked-Acidic-Dipeptidase inhibitors; 5-phosphonomethyl-1,3-benzenedicarboxylic Acid; glutamate abnormalities, anticancer, antidiabetic agent, angiogenesis inhibitor, neuropathy, pain, compulsive disorders, prostate diseases, glaucoma | GUILFORD PHARMACEUTICALS INC. | 2005-08-04 | — | — | US | disclosed |
| US-20050080139-A1 | Naaladase inhibitors for treating huntington's disease | GUILFORD PHARMACEUTICALS INC. | 2005-04-14 | — | — | US | disclosed |
| US-6852750-B2 | Benzenedicarboxylic acid derivatives | GUILFORD PHARMACEUTICALS, INC. (US) | 2005-02-08 | — | — | US | disclosed |
| US-20030083505-A1 | Spinal cord injury, demyelinating diseases, Parkinson's disease, Amyotrophic Lateral Sclerosis, alcohol, nicotine, cocaine dependence, neuropathy, pain and schizophrenia; antiischemic, - carcinogenic agents; NAALADase inhibitors | EISAI INC. | 2003-05-01 | — | — | US | disclosed |
| US-20030036534-A1 | Naaladase inhibitors for treating retinal disorders and glaucoma | EISAI INC. | 2003-02-20 | — | — | US | disclosed |
| US-6452044-B2 | NERVOUS SYSTEM AND PSYCHOLOGICAL DISORDERS | GUILFORD PHARMACEUTICALS INC. | 2002-09-17 | — | — | US | disclosed |
| US-20020019430-A1 | Nervous system and psychological disorders | EISAI INC. | 2002-02-14 | — | — | US | disclosed |
| US-20020013295-A1 | Naaladase inhibitors for treating amyotrophic lateral sclerosis | GUILFORD PHARMACEUTICALS INC., A DELAWARE CORPORATION | 2002-01-31 | — | — | US | disclosed |
| WO-2001092273-A2 | BENZENEDICARBOXYLIC ACID DERIVATIVES | GUILFORD PHARMACEUTICALS INC. (US) | 2001-12-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020013295-A1 | Naaladase inhibitors for treating amyotrophic lateral sclerosis | SMN1; SMN2, GAA, NAALAD2 | KDM4E 1863/4885ALDH1A1 814/4885HSD17B10 1572/4885 |
| US-20030083505-A1 | Spinal cord injury, demyelinating diseases, Parkinson's disease, Amyotrophic Lateral Sclerosis, alcohol, nicotine, cocaine dependence, neuropathy, pain and schizophrenia; antiischemic, - carcinogenic agents; NAALADase inhibitors | NGF, GAP43, ACHE | KDM4E 4182/4885ALDH1A1 110/4885HSD17B10 2186/4885 |
| US-20050080139-A1 | Naaladase inhibitors for treating huntington's disease | HTT, GAA, ADA | KDM4E 2554/4885ALDH1A1 944/4885HSD17B10 418/4885 |
| US-20050171065-A1 | NAALADas, N-Acetylated-Alpha-Linked-Acidic-Dipeptidase inhibitors; 5-phosphonomethyl-1,3-benzenedicarboxylic Acid; glutamate abnormalities, anticancer, antidiabetic agent, angiogenesis inhibitor, neuropathy, pain, compulsive disorders, prostate diseases, glaucoma | NAALAD2, GLUL, DNPEP | KDM4E 3314/4885ALDH1A1 117/4885HSD17B10 1053/4885 |
| US-20020019430-A1 | Nervous system and psychological disorders | GLUL, DDC, DNPEP | KDM4E 2369/4885ALDH1A1 228/4885HSD17B10 965/4885 |
| US-20030036534-A1 | Naaladase inhibitors for treating retinal disorders and glaucoma | ALDH1A2, GAA, PDE6A | KDM4E 2355/4885ALDH1A1 198/4885HSD17B10 622/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.